Literature DB >> 20638047

Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.

James M Stone1, Oliver D Howes, Alice Egerton, Joseph Kambeitz, Paul Allen, David J Lythgoe, Ruth L O'Gorman, Mary A McLean, Gareth J Barker, Philip McGuire.   

Abstract

BACKGROUND: Animal models of psychosis propose that striatal hyperdopaminergia is driven by abnormalities in hippocampal glutamatergic neurotransmission, but this has never been tested in humans.
METHODS: Sixteen individuals with an at-risk mental state for psychosis (ARMS) and 12 control subjects underwent proton magnetic resonance spectroscopy to estimate hippocampal glutamate and [18F]DOPA positron emission tomography to index striatal dopamine function. The relationship between hippocampal glutamate and striatal dopamine, as well as their relationship with prodromal symptoms, was determined using linear regression.
RESULTS: In ARMS subjects, but not controls, there was a significant negative relationship between hippocampal glutamate levels and striatal [18F]DOPA uptake (p = .03). Within the ARMS sample, striatal [18F]DOPA uptake was correlated with severity of abnormal beliefs (p = .03), there was a trend for hippocampal glutamate levels to be correlated with disordered speech (p = .06) and a trend for the interaction between hippocampal glutamate and [18F]DOPA uptake to predict later transition to psychosis (p = .07).
CONCLUSIONS: The relationship between hippocampal glutamate and striatal dopamine systems is altered in people at high risk of psychosis, and the degree to which it is changed may be related to the risk of transition to psychosis. Pharmacologic modulation of the glutamate system before the onset of psychosis might ameliorate this risk.
Copyright © 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638047     DOI: 10.1016/j.biopsych.2010.05.034

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  55 in total

1.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

2.  Evidence for an anterior-posterior differentiation in the human hippocampal formation revealed by meta-analytic parcellation of fMRI coordinate maps: focus on the subiculum.

Authors:  Henry W Chase; Mareike Clos; Sofia Dibble; Peter Fox; Anthony A Grace; Mary L Phillips; Simon B Eickhoff
Journal:  Neuroimage       Date:  2015-03-14       Impact factor: 6.556

Review 3.  Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.

Authors:  Moonnoh R Lee; Aleksandar Denic; David J Hinton; Prasanna K Mishra; Doo-Sup Choi; Istvan Pirko; Moses Rodriguez; Slobodan I Macura
Journal:  Bioanalysis       Date:  2012-07       Impact factor: 2.681

Review 4.  The prodrome and clinical risk for psychotic disorders.

Authors:  Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

5.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

6.  Probabilistic Category Learning and Striatal Functional Activation in Psychosis Risk.

Authors:  Nicole R Karcher; Jessica P Y Hua; John G Kerns
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

Review 7.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

8.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

9.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

10.  The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.

Authors:  Brandon Abbs; Rashmin M Achalia; Adegoke O Adelufosi; Ahmet Yiğit Aktener; Natalie J Beveridge; Savita G Bhakta; Rachael K Blackman; Emre Bora; M S Byun; Maurice Cabanis; Ricardo Carrion; Christina A Castellani; Tze Jen Chow; M Dmitrzak-Weglarz; Charlotte Gayer-Anderson; Felipe V Gomes; Kristen Haut; Hiroaki Hori; Joshua T Kantrowitz; Taishiro Kishimoto; Frankie H F Lee; Ashleigh Lin; Lena Palaniyappan; Meina Quan; Maria D Rubio; Sonia Ruiz de Azúa; Saddichha Sahoo; Gregory P Strauss; Aleksandra Szczepankiewicz; Andrew D Thompson; Antonella Trotta; Laura M Tully; Hiroyuki Uchida; Eva Velthorst; Jared W Young; Anne O'Shea; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-08-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.